A randomized, placebo-controlled clinical study of an anti-PD-1 checkpoint inhibitor with adjunctive microbiome therapy (SER-401) in patients with advanced metastatic melanoma
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2018
At a glance
- Drugs SER-401 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Aug 2018 According to a Seres Therapeutics media release, company is advancing work with collabarator at MD Anderson Cancer Center and the Parker Institute for Immunotherapy to begin a Phase 1b study.
- 02 Aug 2018 According to a Seres Therapeutics media release,study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end .
- 21 Nov 2017 New trial record